These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 11703569)

  • 1. Therapeutic management of hepatitis B-related cirrhosis.
    Merle P; Trepo C
    J Viral Hepat; 2001 Nov; 8(6):391-9. PubMed ID: 11703569
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antiviral therapy in patients with chronic hepatitis B and cirrhosis.
    Lai CJ; Terrault NA
    Gastroenterol Clin North Am; 2004 Sep; 33(3):629-54, x-xi. PubMed ID: 15324948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of chronic hepatitis B: case selection and duration of therapy.
    Leung N
    J Gastroenterol Hepatol; 2002 Apr; 17(4):409-14. PubMed ID: 11982721
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of viral hepatitis B.
    Pramoolsinsup C
    J Gastroenterol Hepatol; 2002 Feb; 17 Suppl():S125-45. PubMed ID: 12000599
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical potential of emerging new agents in hepatitis B.
    Farrell GC
    Drugs; 2000 Oct; 60(4):701-10. PubMed ID: 11085196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures.
    Lavanchy D
    J Viral Hepat; 2004 Mar; 11(2):97-107. PubMed ID: 14996343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis.
    Kanwal F; Gralnek IM; Martin P; Dulai GS; Farid M; Spiegel BM
    Ann Intern Med; 2005 May; 142(10):821-31. PubMed ID: 15897532
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy of granulocyte-macrophage colony-stimulating factor or lamivudine combination with recombinant interferon in non-responders to interferon in hepatitis B virus-related chronic liver disease patients.
    Guptan RC; Thakur V; Kazim SN; Sarin SK
    J Gastroenterol Hepatol; 2002 Jul; 17(7):765-71. PubMed ID: 12121506
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Interferon in hepatitis B].
    García Buey L; González Mateos F; Moreno Otero R
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 7():19-31. PubMed ID: 19100228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Antiviral treatment of chronic hepatitis B virus infections: the past, the present and the future.
    Férir G; Kaptein S; Neyts J; De Clercq E
    Rev Med Virol; 2008; 18(1):19-34. PubMed ID: 17966115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Severe exacerbation of chronic hepatitis B after emergence of lamivudine resistance in a cirrhotic patient: immediate switch to adefovir dipivoxil appears to be indicated.
    Wiegand J; Tischendorf JJ; Nashan B; Klempnauer J; Flemming P; Niemann P; Rohde P; Manns MP; Trautwein C; Tillmann HL
    Z Gastroenterol; 2004 Jan; 42(1):15-8. PubMed ID: 14997399
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Determinants of early mortality and benefits of lamivudine therapy in patients with hepatitis B virus-related decompensated liver cirrhosis.
    Tseng PL; Lu SN; Tung HD; Wang JH; Changchien CS; Lee CM
    J Viral Hepat; 2005 Jul; 12(4):386-92. PubMed ID: 15985009
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy and safety of Entecavir monotherapy switched from Lamivudine combined Adefovir Dipivoxil for chronic hepatitis B virus-related compensated liver cirrhosis].
    Lai XJ; Lian JS; Chen JY; Zhang YM; Jia HY; Zheng L; Yang YD
    Zhonghua Gan Zang Bing Za Zhi; 2018 Feb; 26(2):113-118. PubMed ID: 29804377
    [No Abstract]   [Full Text] [Related]  

  • 14. Natural course, therapeutic options and economic evaluation of therapies for chronic hepatitis B.
    Han SH
    Drugs; 2006; 66(14):1831-51. PubMed ID: 17040114
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A clinical study of adefovir dipivoxil treatment for chronic hepatitis patients with cirrhosis in their decompensation period].
    Yang Q; Gong ZJ; Hu DF
    Zhonghua Gan Zang Bing Za Zhi; 2009 Jul; 17(7):515-9. PubMed ID: 19912686
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Effects of antiviral agents on intrahepatic ccc DNA in HBeAg-positive chronic hepatitis B patients].
    Lu HY; Zhuang LW; Yu YY; Si CW; Li J
    Zhonghua Gan Zang Bing Za Zhi; 2008 Mar; 16(3):198-202. PubMed ID: 18364079
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of interferon and lamivudine treatment in Japanese patients with HBeAg positive chronic hepatitis B.
    Arase Y; Ikeda K; Suzuki F; Suzuki Y; Kobayashi M; Akuta N; Hosaka T; Sezaki H; Yatsuji H; Kawamura Y; Kobayashi M; Kumada H
    J Med Virol; 2007 Sep; 79(9):1286-92. PubMed ID: 17607775
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of HBeAg-negative chronic hepatitis B.
    Hadziyannis SJ; Papatheodoridis GV; Vassilopoulos D
    Semin Liver Dis; 2003 Feb; 23(1):81-8. PubMed ID: 12616453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current pharmacotherapy for hepatitis B infection.
    Galan MV; Boyce D; Gordon SC
    Expert Opin Pharmacother; 2001 Aug; 2(8):1289-98. PubMed ID: 11584997
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of patients with decompensated HBV cirrhosis.
    Fontana RJ
    Semin Liver Dis; 2003 Feb; 23(1):89-100. PubMed ID: 12616454
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.